HeXun Biosciences CoROCO:6986 23 ROA % is 18.15% as of Dec. 2025, which is 164% above its 10-year median of 6.87. GuruFocus rates ROCO:6986 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, HeXun Biosciences Co ranks better than 89.55% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. HeXun Biosciences Co's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$147.9 Mil.
HeXun Biosciences Co's average Total Assets over the quarter that ended in Dec. 2025 was NT$814.9 Mil. Therefore, HeXun Biosciences Co's annualized ROA % for the quarter that ended in Dec. 2025 was 18.15%.
The historical rank and industry rank for HeXun Biosciences Co's ROA % or its related term are showing as below:
ROCO:6986'
s ROA % Range Over the Past 10 Years
Min: -15.33 Med: 6.87 Max: 23.03
Current: 6.48
During the past 6 years, HeXun Biosciences Co's highest ROA % was 23.03%. The lowest was -15.33%. And the median was 6.87%.
ROCO:6986's ROA % is ranked better than 89.55% of 1416
companies
in the Biotechnology industry
Industry Median: -32.87
vs ROCO:6986: 6.48
HeXun Biosciences Co (ROCO:6986) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HeXun Biosciences Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeXun Biosciences Co ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's ROA % distribution charts can be found below:
* The bar in red indicates where HeXun Biosciences Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
HeXun Biosciences Co (ROCO:6986) has a ROA % of 18.15% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on HeXun Biosciences Co and its competitors. This is 164% above median its historical median of 6.87. According to the industry distribution chart, HeXun Biosciences Co ranks #148 out of 1416 companies in the Biotechnology industry, placing it in the top 10.5%.
Is HeXun Biosciences Co's ROA % too high?
HeXun Biosciences Co's current ROA % of 18.15% is 164% above median its 10-year median of 6.87. Based on the distribution chart, HeXun Biosciences Co ranks #148 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HeXun Biosciences Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HeXun Biosciences Co ranks #148 out of 1416 companies for ROA %. This places HeXun Biosciences Co in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on HeXun Biosciences Co and its competitors. HeXun Biosciences Co's current ROA % is 18.15%, which is 164% above median its own 10-year median of 6.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current ROA % of 18.15%. The current ROA % is 18.15%, which is 164% above median its 10-year median of 6.87. HeXun Biosciences Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current ROA % is 18.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
23GF Score
Get the complete analysis for ROCO:6986
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6986 has been successfully added to your 
